Antimalarial medication multi-drug resistant "P. falciparum". It is a very potent blood schizonticide with a long half-life. It is thought to act by forming toxic heme complexes that damage parasitic food vacuoles. Mefloquine is effective in prophylaxis and for acute therapy. It is now used solely for the prevention of resistant strains of "P. falciparum" (usually combined with Artesunate) despite being effective against "P. vivax", "P. ovale" and "P. marlariae". Chloroquine/proguanil or sulfa drug-pyrimethamine combinations should be used in all other plasmodia infections. The major commercial manufacturer of mefloquine-based malaria treatment is Roche Pharmaceuticals, which markets the drug under the trade name
International Association for the Treatment of Sexual Offenders (every single person's treatment and care is going to be different to what best fits that specific person). Every sex offender is different which is why their care and limits need to be properly customized for that individual in order to protect the people of the community and also to successfully prevent them from reoffending. The management of risk is an important part of treatment, but if there is only a limited focus on risk then it can lead to excessively confrontational therapeutic encounters, no close relationship between the offenders and clinicians (this can potentially make treatment unsuccessful because there